Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Companion to Protocol 2010-0085
To perform a DCE-CT scan, a small amount of a special dye (called "CT contrast medium") is
injected by vein into the body. Several CT images are then taken over a few minutes to
learn how much dye spreads outside of the tumor. This can show how much blood flows to and
from the tumor. By performing DCE-CT scans after several weeks on treatment, researchers
may learn if changes in blood flow may be a sign that the treatment is working.
Study Procedures:
If you are found to be eligible to take part in this study, you will have a DCE-CT scan to
check the status of the disease at the following times:
- Within about 4 weeks before you begin treatment on study 2010-0085.
- Eight (8) weeks after starting treatment on study 2010-0085.
Before each of the DCE-CT scans are performed, blood (about 1 tablespoon) will be drawn to
check your kidney function.
If your doctor thinks it is needed, you will also have a standard-of-care CT scan at these
timepoints to check the status of the disease.
Length of Study:
Your participation in this study will be over after the scan(s) 8 weeks after starting
treatment on study 2010-0085. You will be taken off of this study if you leave the
2010-0085 study early.
This is an investigational study. The DCE-CT scan is commercially available. Using DCE-CT
scans to check the status of kidney cancer is investigational.
Up to 60 patients will take part in this study. All will be enrolled at M. D. Anderson.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Blood Flow (BF) Reduction
Changes in perfusion parameters assessed at first re-staging (approximately 8 weeks) and shortly after initiating therapy (2 - 7 days), for three different therapies using organ-directed DCE-CT tumor assessments.
From 4 weeks prior to first dose to 8 weeks post treatment
No
Chaan Ng, MD
Principal Investigator
UT MD Anderson Cancer Center
United States: Food and Drug Administration
2009-0845
NCT01224288
January 2011
Name | Location |
---|---|
UT MD Anderson Cancer Center | Houston, Texas 77030 |